Horizon Therapeutics [HZNP] vs Eli Lilly and [LLY] Detailed Stock Comparison

Horizon Therapeutics

NASDAQ

Eli Lilly and

NYSE

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Horizon Therapeutics wins in 8 metrics, Eli Lilly and wins in 9 metrics, with 0 ties. Eli Lilly and appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric	Horizon Therapeutics	Eli Lilly and	Better
P/E Ratio (TTM)	61.86	46.30	Eli Lilly and
Price-to-Book Ratio	5.01	34.84	Horizon Therapeutics
Debt-to-Equity Ratio	0.48	217.89	Horizon Therapeutics
PEG Ratio	-16.29	0.50	Horizon Therapeutics
EV/EBITDA	24.08	27.19	Horizon Therapeutics
Profit Margin (TTM)	74.64%	25.91%	Horizon Therapeutics
Operating Margin (TTM)	16.83%	45.81%	Eli Lilly and
EBITDA Margin (TTM)	16.83%	45.81%	Eli Lilly and
Return on Equity	10.28%	86.29%	Eli Lilly and
Return on Assets (TTM)	5.72%	16.55%	Eli Lilly and
Free Cash Flow (TTM)	N/A	$414.30M	N/A
Dividend Yield	N/A	0.52%	N/A
1-Year Return	-6.82%	-25.30%	Horizon Therapeutics
Price-to-Sales Ratio (TTM)	7.34	11.95	Horizon Therapeutics
Enterprise Value	$26.84B	$673.74B	Eli Lilly and
EV/Revenue Ratio	7.40	12.65	Horizon Therapeutics
Gross Profit Margin (TTM)	76.72%	84.27%	Eli Lilly and
Revenue per Share (TTM)	$16	$59	Eli Lilly and
Earnings per Share (Diluted)	$2.22	$15.33	Eli Lilly and
Beta (Stock Volatility)	N/A	0.44	N/A

Performance

Key Stats

Valuation

Financials

Short Interest

Dividends

Horizon Therapeutics vs Eli Lilly and Stock Performance Analysis

Loading Price Chart...

Performance Comparison

Short-term Returns

Stock	1D	1W	1M	3M	6M	YTD
Horizon Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Eli Lilly and	0.26%	1.49%	-8.34%	-0.49%	-19.26%	-8.53%

Long-term Returns

Stock	1Y	3Y	5Y	10Y	15Y	20Y
Horizon Therapeutics	-6.82%	74.04%	9.84%	176.66%	176.66%	176.66%
Eli Lilly and	-25.30%	125.53%	383.02%	755.49%	1,980.94%	1,232.48%

Performance Comparison

This comparison requires JavaScript for dynamic charts and real-time data. For complete performance analysis, visit the individual stock overview pages:

Horizon Therapeutics (HZNP): View Full Stock Overview

Eli Lilly and (LLY): View Full Stock Overview

The individual stock overview pages contain detailed performance metrics, historical charts, financial data, and comparison tools that work without JavaScript.

Key Performance Metrics Available:

Daily, weekly, monthly, and yearly returns
52-week high and low prices
Market capitalization and valuation ratios
Financial health and profitability metrics
Dividend history and yield information

Performance & Financial Health Analysis: Horizon Therapeutics vs Eli Lilly and

Metric	HZNP	LLY
Market Information
Market Cap i	$26.63B	$636.32B
Market Cap Category	Large cap	Mega cap
10 Day Avg. Volume i	19,134,206	7,393,770
90 Day Avg. Volume i	8,460,695	5,686,893
Last Close	$116.30	$711.68
52 Week Range	$116.30 - $116.34	$623.78 - $972.53
% from 52W High	-0.03%	-26.82%
All-Time High	$39.49 (Jul 20, 2015)	$972.53 (Aug 19, 2024)
% from All-Time High	194.50%	-26.82%
Growth Metrics
Quarterly Revenue Growth	0.14%	0.38%
Quarterly Earnings Growth	N/A	0.91%
Financial Health
Profit Margin (TTM) i	0.75%	0.26%
Operating Margin (TTM) i	0.17%	0.46%
Return on Equity (TTM) i	0.10%	0.86%
Debt to Equity (MRQ) i	0.48	217.89
Cash & Liquidity
Book Value per Share (MRQ)	$23.22	$20.38
Cash per Share (MRQ)	N/A	$3.95
Operating Cash Flow (TTM) i	$1.33B	$10.94B
Levered Free Cash Flow (TTM) i	$1.81B	$-2,265,437,440
Dividends
Last 12-Month Dividend Yield i	N/A	0.52%
Last 12-Month Dividend i	N/A	$4.10

Valuation & Enterprise Metrics Analysis: Horizon Therapeutics vs Eli Lilly and

Metric	HZNP	LLY
Price Ratios
P/E Ratio (TTM) i	61.86	46.30
Forward P/E i	20.55	31.32
PEG Ratio i	-16.29	0.50
Price to Sales (TTM) i	7.34	11.95
Price to Book (MRQ) i	5.01	34.84
Market Capitalization
Market Capitalization i	$26.63B	$636.32B
Enterprise Value i	$26.84B	$673.74B
Enterprise Value Metrics
Enterprise to Revenue i	7.40	12.65
Enterprise to EBITDA i	24.08	27.19
Risk & Other Metrics
Beta i	N/A	0.44
Book Value per Share (MRQ) i	$23.22	$20.38

Financial Statements Comparison: Horizon Therapeutics vs Eli Lilly and

Financial Metrics

Loading Financial Charts...

Revenue

EBITDA

Shareholders Equity

Operating Margin

Free Cash Flow

Long Term Debt

Profit Margin

Current Ratio

Operating Cash Flow

Income Statement (MRQ)

Metric (MRQ)	HZNP	LLY
Revenue/Sales i	N/A	$12.73B
Cost of Goods Sold i	N/A	$2.22B
Gross Profit i	N/A	$10.50B
Research & Development i	N/A	$2.73B
Operating Income (EBIT) i	N/A	$5.41B
EBITDA i	N/A	$5.92B
Pre-Tax Income i	N/A	$3.46B
Income Tax i	N/A	$696.80M
Net Income (Profit) i	N/A	$2.76B

Balance Sheet & Liquidity Metrics (MRQ)

Metric (MRQ)	HZNP	LLY
Cash & Equivalents i	N/A	$3.09B
Total Current Assets i	N/A	$41.26B
Total Current Liabilities i	N/A	$30.07B
Long-Term Debt i	N/A	$34.50B
Total Shareholders Equity i	N/A	$15.85B
Retained Earnings i	N/A	$15.10B
Property, Plant & Equipment i	N/A	N/A

Cash Flow Statement Comparison (MRQ)

Metric (MRQ)	HZNP	LLY
Operating Cash Flow i	N/A	$4.88B
Capital Expenditures i	N/A	$-1.51B
Free Cash Flow i	N/A	$-1.60B
Debt Repayment i	N/A	N/A
Common Stock Repurchase i	N/A	$-1.20B

Short Interest & Institutional Ownership Analysis

Metric	HZNP	LLY
Shares Short i	N/A	7.17M
Short Ratio i	N/A	2.20
Short % of Float i	N/A	0.01%
Average Daily Volume (10 Day) i	19,134,206	7,393,770
Average Daily Volume (90 Day) i	8,460,695	5,686,893
Shares Outstanding i	229.00M	897.54M
Float Shares i	N/A	895.44M
% Held by Insiders i	N/A	0.00%
% Held by Institutions i	N/A	0.84%

Dividend Analysis & Yield Comparison: Horizon Therapeutics vs Eli Lilly and

Metric	HZNP	LLY
Last 12-Month Dividend i	N/A	$4.10
Last 12-Month Dividend Yield i	N/A	0.52%
3-Year Avg Annual Dividend i	N/A	$4.02
3-Year Avg Dividend Yield i	N/A	0.22%
3-Year Total Dividends i	N/A	$12.05
Ex-Dividend Date	N/A	Feb 14, 2025

Horizon Therapeutics [HZNP] vs Eli Lilly and [LLY] Detailed Stock Comparison